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the new antipsychotic users. The outcome was time to first foster care placement 
transition during a 180-day follow-up. Cox proportional hazard models estimated 
hazard ratios (HRs) associated with antipsychotic initiation, adjusting for demo-
graphic, clinical, and foster care characteristics. RESULTS: Comparing new users to 
propensity-score matched nonusers, there was no difference regarding average days 
to placement transition (109 versus 113 days). The proportion experiencing a foster 
care placement transition (37% versus 36%) during the follow-up. The HR was 1.1 (95% 
CI: 0.7-1.6). CONCLUSIONS: Youth initiating antipsychotics had no significant reduc-
tion in foster placement transitions within the 180-day follow-up. Although antipsy-
chotics are widely used for aggressive behaviors, a better understanding of clinical 
management of youth in foster care is needed to promote stable foster placement.
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OBJECTIVES: The investigation was undertaken to determine the treatment pat-
tern used in psychiatric patients and also to determine the symptoms, risk fac-
tors and clinical presentation of patients with psychiatric diseases. METHODS: 
The present observational study was carried out at a tertiary care psychiatry 
hospital in Warangal, India over a period of six months. Three hundred prescrip-
tions were collected and analyzed according to the recommendations of World 
Health Organization. RESULTS: It was found that schizophrenia (45%, n= 147) 
is the most common among the study population followed by depression (31%, 
n= 122). Dementia was the least detected (5%, n= 8) psychiatric condition. Among 
Schizophrenia patients, mostly were administered with lorazepam (n= 131). On the 
other hand, amisulpride was found to be administered in fewer patients. Among 
29 anxiety patients, lorazepam was found to be widely used and fluvoxamine, pro-
pranolol, trazodone and mirtazapine were used in fewer number. Among Dementia 
patients mostly used drug was donepezil (n= 13). CONCLUSIONS: The study revealed 
the anti-psychotic drug utilization pattern in a tertiary care hospital of Warangal city 
(an historic city of south India). Among the study population, dementia was the least 
detected case. Schizophrenia and anxiety patients were mostly administered with 
lorazepam and however, among dementia patients, mostly used drug was donepezil.
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OBJECTIVES: Atypical antipsychotics (AAP) are commonly used to treat off-
label conditions such as anxiety, depression, and post-traumatic stress disorder. 
Despite a black box warning in 2005, AAP still remain the second most common 
therapeutic class used for dementia. The objective of the study is to determine 
resource utilization (RU) and costs in patients using AAP to treat off-label condi-
tions. METHODS: A retrospective cross-sectional study was conducted using 2009 
Medical Expenditure Survey (MEPS) data. Study sample included individuals aged 
≥ 18 years with at least 2 claims for AAP identified from the Prescribed Medicines 
file. Indications were identified using ICD-9-CM and CCCODEX codes from the 
Medical Conditions file. Schizophrenia and bipolar disorder were categorized 
as FDA approved indications; all other indications were categorized as off-label 
use. RU and costs were obtained from the Full-Year Consolidated Files. RESULTS: 
N= 352 patients had at least 2 claims for AAP. 55.7% were off-label users with 
1,442 AAP claims. The most common off-label conditions were depressive disorder 
(29.89% of claims), neurotic disorders (15.40%) and general symptoms (13.80%). 
5.20% of the claims were for dementia. The typical off-label AAP user was female 
(60.20%), White (67.86%) with mean age 51.11+16.81 years (R: 18-85). Mean RU for 
off-label users was 14.61+16.79 (0-138) office-based provider visits, 1.41+3.94 (0-32) 
hospital-outpatient visits, 0.61+1.38 (0-12) ED visits, and 0.36+0.83 (0-4) inpatient 
discharges. The average total cost was $13,751.64 per person. For FDA approved 
users, mean RU was 17.77+26.73 (0-216) office-based provider visits, 2.51+11.83 
(0-123) hospital-outpatient visits, 0.71+1.22 (0-7) ED visits, and 0.39+0.84 (0-5) inpa-
tient discharges. The average total cost was $14,573.93 per person. CONCLUSIONS: 
Off-label prescribing of AAP is still a prevalent practice and needs to be monitored. 
Future research will compare RU and costs among patients prescribed and not 
prescribed AAP for off-label indications.
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OBJECTIVES: To describe and evaluate health resource use (HRU) of schizophrenia 
patients enrolled to JANSSEN CONNECT® (JC). METHODS: This is a multi-center, 
retrospective medical chart review of patients enrolled in JC, a comprehensive 
information and assistance program that supports patients after a healthcare 
professional has determined a Janssen long-acting injectable atypical antipsy-
chotic to be the most clinically appropriate treatment option.  Data collected 
included demographic and clinical characteristics, HRU, outpatient and injection 
appointments (missed and completed) and medication usage. The index date was 
defined as LAI initiation date where new users initiated LAI on/after JC enrollment 
while continuous users initiated LAI prior to enrollment.  Descriptive analysis 
was conducted to evaluate the demographic, clinical characteristics and HRU of 
JC enrollees at 6-month pre- and post-index periods. Comparative analysis on 
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OBJECTIVES: Approximately 4.1% of the U.S. adult population suffers from serious 
mental illness (SMI). Those dually eligible for Medicare and Medicaid suffer dispro-
portionately from SMI (~30%). Antipsychotic medications can significantly improve 
the lives of people with SMI, but can have a variety of adverse effects, which may 
be exacerbated by polypharmacy. Antipsychotic nonadherence is also problematic. 
The real-world observation of antipsychotic utilization patterns has been identi-
fied as a priority. We assessed utilization of antipsychotics and other psychotropic 
medications among dually-eligible adults with SMI, including calculations of adher-
ence, discontinuation, switching and polypharmacy. METHODS: The Medicare Part 
D Drug Event (PDE) file was used to identify Washington State dual-eligibles who 
filled an antipsychotic prescription in 2010. Twelve-month antipsychotic utilization 
rates were broken down by class (typical or atypical), and by medication. Adherence 
was measured using the proportion-of-days-covered methodology. For nonadher-
ent beneficiaries we distinguished between those who discontinued use and those 
who switched to another antipsychotic. Rates of antipsychotic polypharmacy in a 
given 30-day period, and antidepressant and mood-stabilizer utilization within the 
12-month observation period were estimated. RESULTS: There were 21,749 WA State 
dual-eligibles who filled an antipsychotic prescription in 2010. Over the 12-month 
observation period, 92% of the sample filled an atypical antipsychotic prescription 
(adherent= 61%, discontinued= 9%, switched= 30%), and 16% filled a typical antipsy-
chotic prescription (adherent= 50%, discontinued= 11%, switched= 39%). Of the 4,307 
duals who used more than one antipsychotic within a 30-day window, 91% used a 
maximum of two medications and only 9% used three or more. Finally, during the 
12-month observation period, 46% of duals filled an antidepressant prescription 
and 23% filled a mood-stabilizer prescription. CONCLUSIONS: This information is 
critical for policymakers looking to improve quality of care and reduce costs, given 
that individuals with SMI often avoid clinical trials and duals accumulate roughly 
$300 billion [2013 USD] in annual healthcare expenditures.
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BACKGROUND: Legal indications for the use of methylphenidate are restricted to 
children diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). Despite its 
defined therapeutic indications, there is a trend in non-prescribed methylphenidate 
off-label use by students and professionals to improve performance. New terms 
related to this trend: academic doping, nootropic, cosmetic neurology or smart 
pill. OBJECTIVES: To describe findings and consequences on methylphenidate’s off-
label use for cognitive enhancement in healthy individuals. METHODS: A systema-
tized search was conducted to retrieve the best scientific evidence on the subject 
available in English, Portuguese or Spanish. RESULTS: One review evaluated nine 
studies on the use of methylphenidate among healthy medical students. The preva-
lence was 16%, with no gender difference. However, there was a higher prevalence 
among those with had a low academic performance. Most students (65.2%) began 
using the drug after starting college. The use was seasonal throughout the year - 
periods close to exams or at the end of the semester were associated with a higher 
demand for the stimulant. There is little evidence in the literature about the effect 
of methylphenidate on the cognition of those without ADHD. There is no evidence 
that the drug increases memorization or associative learning, only that it makes 
people more alert, but with their selective attention capacity reduced. Some studies 
suggest that stimulants may interfere with neural mechanisms for the consolida-
tion of learning and long-term memory, which is a risk for intellectual performance. 
Also, methylphenidate increases heart rate and blood pressure, potentially more 
worrying in adults than children due to possible associations with other substances 
and reports of sudden deaths and side psychiatric effects. CONCLUSIONS: Although 
we currently live in a highly competitive environment, it’s important to adopt social 
interventions that focus on the misuse of methylphenidate, alerting the public and 
focusing on the consequences of its non-prescribed use.
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OBJECTIVES: Attention-deficit hyperactivity/disruptive behavior disorders (ADHD/
DBD) often lead to multiple placement transitions among youth in foster care. 
Increasingly, antipsychotic medications are used off-label to manage disruptive 
behaviors. There is limited evidence of the impact of antipsychotic management of 
ADHD/DBD on placement stability among fostered youth. This study is to investigate 
the association between antipsychotic initiation and time to first foster care place-
ment transition among antipsychotic users and propensity-score matched nonus-
ers. METHODS: All youth (n= 18,034) involved in foster care anytime from January 
1, 2010 through March 31, 2014 in one Mid-Atlantic state were identified. Data were 
from child welfare administrative records linked with Medicaid claims. The index date 
was identified by filling the first antipsychotic prescription in 2010-2013. New antip-
sychotic users were restricted to youth with (1) continuous foster care involvement 
180 days preceding and following the index date, (2) any diagnosis of ADHD, conduct 
disorder, oppositional defiant disorder, impulsive control, and (3) no antipsychotics 
180 days before the index date. Propensity-score matched nonusers were defined as 
youth with no antipsychotic use in 2010-2013 and met the same selection criteria as 
